 polymerase){kind=link}
In a significant development for antiviral research, scientists have published a study in Cell that sheds new light on the complex workings of the herpes simplex virus (HSV) polymerase, a critical enzyme in the virus’s replication process. This research could have far-reaching implications for improving antiviral therapies, particularly for drugs targeting HSV and other related viruses.
The study focuses on a family of enzymes known as family B DNA polymerases, which include essential players in DNA replication, such as eukaryotic DNA polymerases α, δ, and ε. Despite a wealth of structural information on these enzymes, a key gap has been understanding how their conformational changes—essentially, their shifts in shape and structure—relate to their function. This knowledge is especially important for viral family B DNA polymerases, which are prime targets for antiviral drugs used to combat infections like poxviruses, adenoviruses, and herpesviruses.
HSV polymerase, in particular, is a well-known target for antiviral drugs such as acyclovir and foscarnet. These drugs are critical for treating HSV infections, but their effectiveness can be compromised by mutations in the viral polymerase. How these mutations lead to drug resistance has remained a mystery—until now.
Using advanced cryo-electron microscopy, the researchers obtained detailed, high-resolution images of the HSV polymerase bound to DNA. These images captured the enzyme in various states, from open to closed conformations, as it engaged in DNA synthesis. By pairing these structural snapshots with molecular dynamics simulations, the team uncovered how specific mutations—some far from the drug binding sites—affect the polymerase’s dynamics and contribute to drug resistance.
Moreover, the study provided new insights into how the polymerase and its processivity subunit, UL42, work together to synthesize DNA efficiently. Unlike its eukaryotic counterpart, which forms a ring around DNA, UL42 binds tightly as a monomer, a unique feature that has puzzled scientists for some time. The new structural data offer clues to how this tight yet dynamic binding supports the rapid and continuous synthesis of viral DNA.
These findings not only deepen our understanding of HSV polymerase but also open up potential new avenues for designing more effective antiviral drugs. By targeting the newly identified mechanisms of drug resistance and processivity, future therapies could be better equipped to combat resistant strains of HSV and possibly other viruses that rely on similar polymerases.